Welcome to our dedicated page for Artelo Biosciences SEC filings (Ticker: ARTL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Artelo Biosciences, Inc. filings document a clinical-stage pharmaceutical issuer with securities listed on Nasdaq and a pipeline centered on lipid-signaling modulation. Registration statements and amendments describe securities offerings, delayed or continuous offering registration mechanics, common stock, warrants, pre-funded warrants and capital-structure terms.
Artelo's Form 8-K filings record material events including Nasdaq continued-listing compliance, annual-meeting matters, private-placement activity, material agreements, and clinical or regulatory disclosures for programs such as ART27.13 and ART26.12. The filings connect formal governance and financing records with updates on the company's drug-development strategy and intellectual-property activity.
Artelo Biosciences, Inc. filed Amendment No. 1 to its Registration Statement (File No. 333-295537) to furnish Exhibit 4.3 and to update Part II disclosures. The amendment includes an estimated SEC registration fee of $788.05 and states a prior registration fee of $7,636.16 associated with $69,293,654.25 of unsold securities that will be carried forward pursuant to Rule 415(a)(6).
The filing restates indemnification provisions under Nevada law, notes indemnification limits for Securities Act liabilities, lists exhibits (including a Form of Indenture filed herewith), and includes customary undertakings regarding post-effective amendments and prospectus updates.
Artelo Biosciences, Inc. is filing a shelf registration to offer up to $75,000,000 of securities, which may include common stock, preferred stock, debt securities, warrants and units. The registration also includes $69,293,654.25 of unsold securities carried forward from a prior registration under Rule 415(a)(6).
The shelf permits offers from time to time; specific terms, pricing and distribution methods will be provided in prospectus supplements. Use of proceeds is generally for working capital and general corporate purposes, with any specific allocation set forth in future prospectus supplements.
Artelo Biosciences is registering up to 9,820,294 shares of Common Stock for resale. The shares consist of 81,000 issued shares, up to 3,107,407 shares issuable on Pre-Funded Warrants, up to 6,376,814 shares issuable on Common Warrants and up to 255,073 shares issuable on Placement Agent Warrants.
The Company is not selling any shares here and will not receive proceeds from resale by the Selling Stockholders; however, Artelo may receive up to $21,508,908.56 in gross proceeds if the Warrants and Placement Agent Warrants are exercised for cash. The prospectus discloses Beneficial Ownership Limitation provisions (4.99% or 9.99% election) and cashless-exercise conditions for certain Warrants.
Artelo Biosciences, Inc. is registering 9,820,294 shares of common stock for resale by existing investors under a Form S-1. The shares relate to an March 27, 2026 private placement of 81,000 shares, 3,107,407 pre-funded warrant shares, 6,376,814 common warrant shares and 255,073 placement agent warrant shares.
Artelo will not receive proceeds from stockholder resales but may receive up to $21.5 million in gross proceeds if the warrants are exercised for cash, which it expects to use for working capital, general corporate purposes and repayment of bridge debt. Its stock trades on Nasdaq as “ARTL,” with a $6.61 closing price on April 6, 2026. The prospectus highlights significant dilution and resale overhang risks for existing holders.
Artelo Biosciences has regained compliance with Nasdaq’s continued listing standards. Nasdaq confirmed the company now meets Listing Rule 5550(b)(1), known as the Equity Rule, and Listing Rule 5620(a), the Annual Shareholders Meeting Rule. Nasdaq will monitor Artelo for one year under a mandatory panel monitor.
The company highlights continued progress across its pipeline, including ART27.13, which showed encouraging Phase 2 CAReS interim data in cancer anorexia-cachexia syndrome and is also being studied in glaucoma, and ART26.12, a non-opioid candidate for neuropathic pain. Management believes this positions Artelo to pursue long-term shareholder value.
Artelo Biosciences ownership disclosure: Reporting Persons Mitchell P. Kopin, Daniel B. Asher and Intracoastal Capital LLC may be deemed to beneficially own 81,701 shares of Common Stock, equal to 9.99% of the class, based on 817,127 shares outstanding as of March 30, 2026. The 81,701 figure consists of 81,000 shares held by Intracoastal and 701 shares issuable upon exercise of Intracoastal Warrant 1. The filing states blocker provisions that exclude 5,256 and 173,914 warrant shares from these counts; without those blockers the Reporting Persons may be deemed to own 260,871 shares.
Artelo Biosciences entered into definitive agreements for a $11.0 million private placement of 3,188,407 shares of common stock (or pre-funded warrants) plus warrants to buy up to 6,376,814 additional shares. Investors will pay $3.45 per share (or pre-funded warrant) with accompanying warrants.
The warrants will have an exercise price of $3.20 per share, be exercisable upon issuance, and expire five and one-half years after the resale registration statement becomes effective. Artelo plans to use net proceeds for working capital, general corporate purposes, and repayment of certain bridge debt.
The securities are being sold in a private placement exempt from registration under Section 4(a)(2) and/or Regulation D, with the company agreeing to file a resale registration statement for these securities.